IJCS | Volume 33, Nº1, January / February 2019

70 Table 1 - Demographic and clinical characteristics of 377 adult patients admitted with atrial fibrillation at a tertiary hospital in Salvador, Bahia, Brazil Variable Without anticoagulant (n = 93) With anticoagulant (n = 284) p* VKA (n = 76) DOACs (n = 208) p† Age (years) 73 ± 18 69 ± 13 0.059 70 ± 13 69 ± 14 0.493 Male 42 (45.2) 155 (54.6) 0.115 41 (53.9) 114 (54.8) 0.897 Weight (kg), n = 370 71.8 ± 15.5 78.4 ± 20.6 0.002 75.8 ± 21.4 79.3 ± 20.3 0.207 Height (meters), n = 370 1.64 ± 0.11 1.66 ± 0.10 0.036 1.65 ± 0.10 1.67 ± 0.10 0.114 SAH 59 (63.4) 210 (73.4) 0.052 59 (77.6) 151 (72.6) 0.392 DM 27 (29) 61 (21.5) 0.135 18 (23.7) 43 (20.7) 0.584 CHF 23 (24.7) 77 (72) 0.652 30 (39.5) 47 (22.6) 0.005 AMI in the past year 10 (10.8) 18 (6.3) 0.159 5 (6.6) 13 (6.3) 0.920 TCA in the past year 4 (4.3) 4 (1.4) 0.093 1 (1.3) 3 (1.4) 0.936 History of TIA/ischemic stroke 25 (26.9) 42 (14.8) 0.008 10 (13.2) 32 (15.4) 0.640 History of hemorrhagic stroke 0 (0) 2 (0.7) 0.417 1 (1.3) 1 (0.5) 0.456 History of AF n=357 42 (50) 191 (70) 0.001 49 (70) 142 (69.9) 0.994 Geraldes et al. Oral anticoagulation in AF Int J Cardiovasc Sci. 2020;33(1):68-78 Original Article the univariate analyseswere later included inmultivariate logistic regression models using the backward stepwise method. The variables that reached p < 0.05 in the final analyses were considered statistically significant. All analyses were conducted in the Statistical Package for the Social Sciences (SPSS) version 23. Ethical issues of research This study was approved in a plenary session at the Ethics ResearchCommittee Prof. Celso Figuerôa, Hospital Santa Izabel on 11-24-2014, according to Resolutions 466/12 and 251/97, protocol number 917.116. Results From 2011 to 2016, there were 464 admissions with diagnosis of AF discharge. Of these, 87 patients were excluded: 28 for not presenting AF (coding error); 26 hospital readmissions; 20 deaths during admission; 13 for not having electronic prescription of discharge. The final population analyzed consisted of 377 patients. Demographic and clinical data Patients were separated into two groups: patients with and without anticoagulants. The group on anticoagulants was subsequently divided into patients using VKA or DOAC (Table 1). The mean age of the patients was 70 ± 15 years, and 52%were male withmean body mass index (BMI) of 27 ± 6. Regarding the type of AF, 42% had paroxysmal AF, 12% had persistent AF, 27% had permanent AF, 19% with indefinite duration; 10% of the patients had atrial flutter. There was a high prevalence of comorbidities, with 71% of hypertensive patients, 23% of diabetics, 26% with a history of heart failure, 7.4% with a history of myocardial infarction and 18% had ischemic stroke. Of the study population, 25% had moderate or severe valvulopathy, 3.9% had biological valve prosthesis and 1.8% had mechanical valve prosthesis (Table 1). Mean CHA 2 DS 2 -VASc risk score was 3.4 ± 2.0 and the HASBLED score was 1.2 ± 1.0, with 11.2% of these having HASBLED 3 and 79.8% having CHA 2 DS 2 -VASc ≥ 2 (Chart 1). Use of anticoagulant therapy Considering the total population over a 5-year period, 75% of the patients were discharged on anticoagulants (20% received VKA and 55% received DOACs), 15% were on antiplatelets alone and 10% were not on antithrombotic therapy.